A novel deubiquitinase inhibitor b-AP15 triggers apoptosis in both androgen receptor-dependent and -independent prostate cancers

Jianyu Cai, Xiaohong Xia, Yuning Liao, Ningning Liu, Zhiqiang Guo, Jinghong Chen, Li Yang, Huidan Long, Qianqian Yang, Xiaolan Zhang, Lu Xiao, Xuejun Wang, Hongbiao Huang, Jinbao Liu

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Prostate cancer (PCa) remains a leading cause of cancer-related death in men. Especially, a subset of patients will eventually progress to the metastatic castrateresistant prostate cancer (CRPC) which is currently incurable. Deubiquitinases (DUBs) associated with the 19S proteasome regulatory particle are increasingly emerging as significant therapeutic targets in numerous cancers. Recently, a novel small molecule b-AP15 is identified as an inhibitor of the USP14/UCHL5 (DUBs) of the 19S proteasome, resulting in cell growth inhibition and apoptosis in several human cancer cell lines. Here, we studied the therapeutic effect of b-AP15 in PCa, and our results indicate that (i) b-AP15 decreases viability, proliferation and triggers cytotoxicity to both androgen receptor-dependent and -independent PCa cells in vitro and in vivo, associated with caspase activation, inhibition of mitochondria function, increased reactive oxygen species (ROS) generation and endoplasmic reticulum (ER) stress; (ii) pan-caspase inhibitor z-VAD-FMK and ROS scavenger N-acetyl-L-cysteine (NAC) efficiently block apoptosis but not proteasome inhibition induced by exposure of b-AP15; (iii) treatment with b-AP15 in androgen-dependent prostate cancer (ADPC) cells down-regulates the expression of androgen receptor (AR), which is degraded via the ubiquitin proteasome system. Hence, the potent anti-tumor effect of b-AP15 on both androgen receptor-dependent and -independent PCa cells identifies a new promising therapeutic strategy for prostate cancer.

Original languageEnglish (US)
Pages (from-to)63232-63246
Number of pages15
JournalOncotarget
Volume8
Issue number38
DOIs
StatePublished - Jan 1 2017
Externally publishedYes

Fingerprint

Androgen Receptors
Prostatic Neoplasms
Apoptosis
Proteasome Endopeptidase Complex
Reactive Oxygen Species
Neoplasms
Endoplasmic Reticulum Stress
Caspase Inhibitors
Acetylcysteine
Therapeutic Uses
Caspases
Ubiquitin
Deubiquitinating Enzymes
Androgens
Mitochondria
Therapeutics
Down-Regulation
Cell Line
Growth

Keywords

  • Apoptosis
  • Deubiquitinase inhibitor
  • Prostate cancer
  • b-AP15

ASJC Scopus subject areas

  • Oncology

Cite this

A novel deubiquitinase inhibitor b-AP15 triggers apoptosis in both androgen receptor-dependent and -independent prostate cancers. / Cai, Jianyu; Xia, Xiaohong; Liao, Yuning; Liu, Ningning; Guo, Zhiqiang; Chen, Jinghong; Yang, Li; Long, Huidan; Yang, Qianqian; Zhang, Xiaolan; Xiao, Lu; Wang, Xuejun; Huang, Hongbiao; Liu, Jinbao.

In: Oncotarget, Vol. 8, No. 38, 01.01.2017, p. 63232-63246.

Research output: Contribution to journalArticle

Cai, J, Xia, X, Liao, Y, Liu, N, Guo, Z, Chen, J, Yang, L, Long, H, Yang, Q, Zhang, X, Xiao, L, Wang, X, Huang, H & Liu, J 2017, 'A novel deubiquitinase inhibitor b-AP15 triggers apoptosis in both androgen receptor-dependent and -independent prostate cancers', Oncotarget, vol. 8, no. 38, pp. 63232-63246. https://doi.org/10.18632/oncotarget.18774
Cai, Jianyu ; Xia, Xiaohong ; Liao, Yuning ; Liu, Ningning ; Guo, Zhiqiang ; Chen, Jinghong ; Yang, Li ; Long, Huidan ; Yang, Qianqian ; Zhang, Xiaolan ; Xiao, Lu ; Wang, Xuejun ; Huang, Hongbiao ; Liu, Jinbao. / A novel deubiquitinase inhibitor b-AP15 triggers apoptosis in both androgen receptor-dependent and -independent prostate cancers. In: Oncotarget. 2017 ; Vol. 8, No. 38. pp. 63232-63246.
@article{87e47ecaa1044fae9b3277c90b4f0936,
title = "A novel deubiquitinase inhibitor b-AP15 triggers apoptosis in both androgen receptor-dependent and -independent prostate cancers",
abstract = "Prostate cancer (PCa) remains a leading cause of cancer-related death in men. Especially, a subset of patients will eventually progress to the metastatic castrateresistant prostate cancer (CRPC) which is currently incurable. Deubiquitinases (DUBs) associated with the 19S proteasome regulatory particle are increasingly emerging as significant therapeutic targets in numerous cancers. Recently, a novel small molecule b-AP15 is identified as an inhibitor of the USP14/UCHL5 (DUBs) of the 19S proteasome, resulting in cell growth inhibition and apoptosis in several human cancer cell lines. Here, we studied the therapeutic effect of b-AP15 in PCa, and our results indicate that (i) b-AP15 decreases viability, proliferation and triggers cytotoxicity to both androgen receptor-dependent and -independent PCa cells in vitro and in vivo, associated with caspase activation, inhibition of mitochondria function, increased reactive oxygen species (ROS) generation and endoplasmic reticulum (ER) stress; (ii) pan-caspase inhibitor z-VAD-FMK and ROS scavenger N-acetyl-L-cysteine (NAC) efficiently block apoptosis but not proteasome inhibition induced by exposure of b-AP15; (iii) treatment with b-AP15 in androgen-dependent prostate cancer (ADPC) cells down-regulates the expression of androgen receptor (AR), which is degraded via the ubiquitin proteasome system. Hence, the potent anti-tumor effect of b-AP15 on both androgen receptor-dependent and -independent PCa cells identifies a new promising therapeutic strategy for prostate cancer.",
keywords = "Apoptosis, Deubiquitinase inhibitor, Prostate cancer, b-AP15",
author = "Jianyu Cai and Xiaohong Xia and Yuning Liao and Ningning Liu and Zhiqiang Guo and Jinghong Chen and Li Yang and Huidan Long and Qianqian Yang and Xiaolan Zhang and Lu Xiao and Xuejun Wang and Hongbiao Huang and Jinbao Liu",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.18774",
language = "English (US)",
volume = "8",
pages = "63232--63246",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "38",

}

TY - JOUR

T1 - A novel deubiquitinase inhibitor b-AP15 triggers apoptosis in both androgen receptor-dependent and -independent prostate cancers

AU - Cai, Jianyu

AU - Xia, Xiaohong

AU - Liao, Yuning

AU - Liu, Ningning

AU - Guo, Zhiqiang

AU - Chen, Jinghong

AU - Yang, Li

AU - Long, Huidan

AU - Yang, Qianqian

AU - Zhang, Xiaolan

AU - Xiao, Lu

AU - Wang, Xuejun

AU - Huang, Hongbiao

AU - Liu, Jinbao

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Prostate cancer (PCa) remains a leading cause of cancer-related death in men. Especially, a subset of patients will eventually progress to the metastatic castrateresistant prostate cancer (CRPC) which is currently incurable. Deubiquitinases (DUBs) associated with the 19S proteasome regulatory particle are increasingly emerging as significant therapeutic targets in numerous cancers. Recently, a novel small molecule b-AP15 is identified as an inhibitor of the USP14/UCHL5 (DUBs) of the 19S proteasome, resulting in cell growth inhibition and apoptosis in several human cancer cell lines. Here, we studied the therapeutic effect of b-AP15 in PCa, and our results indicate that (i) b-AP15 decreases viability, proliferation and triggers cytotoxicity to both androgen receptor-dependent and -independent PCa cells in vitro and in vivo, associated with caspase activation, inhibition of mitochondria function, increased reactive oxygen species (ROS) generation and endoplasmic reticulum (ER) stress; (ii) pan-caspase inhibitor z-VAD-FMK and ROS scavenger N-acetyl-L-cysteine (NAC) efficiently block apoptosis but not proteasome inhibition induced by exposure of b-AP15; (iii) treatment with b-AP15 in androgen-dependent prostate cancer (ADPC) cells down-regulates the expression of androgen receptor (AR), which is degraded via the ubiquitin proteasome system. Hence, the potent anti-tumor effect of b-AP15 on both androgen receptor-dependent and -independent PCa cells identifies a new promising therapeutic strategy for prostate cancer.

AB - Prostate cancer (PCa) remains a leading cause of cancer-related death in men. Especially, a subset of patients will eventually progress to the metastatic castrateresistant prostate cancer (CRPC) which is currently incurable. Deubiquitinases (DUBs) associated with the 19S proteasome regulatory particle are increasingly emerging as significant therapeutic targets in numerous cancers. Recently, a novel small molecule b-AP15 is identified as an inhibitor of the USP14/UCHL5 (DUBs) of the 19S proteasome, resulting in cell growth inhibition and apoptosis in several human cancer cell lines. Here, we studied the therapeutic effect of b-AP15 in PCa, and our results indicate that (i) b-AP15 decreases viability, proliferation and triggers cytotoxicity to both androgen receptor-dependent and -independent PCa cells in vitro and in vivo, associated with caspase activation, inhibition of mitochondria function, increased reactive oxygen species (ROS) generation and endoplasmic reticulum (ER) stress; (ii) pan-caspase inhibitor z-VAD-FMK and ROS scavenger N-acetyl-L-cysteine (NAC) efficiently block apoptosis but not proteasome inhibition induced by exposure of b-AP15; (iii) treatment with b-AP15 in androgen-dependent prostate cancer (ADPC) cells down-regulates the expression of androgen receptor (AR), which is degraded via the ubiquitin proteasome system. Hence, the potent anti-tumor effect of b-AP15 on both androgen receptor-dependent and -independent PCa cells identifies a new promising therapeutic strategy for prostate cancer.

KW - Apoptosis

KW - Deubiquitinase inhibitor

KW - Prostate cancer

KW - b-AP15

UR - http://www.scopus.com/inward/record.url?scp=85029813632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029813632&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.18774

DO - 10.18632/oncotarget.18774

M3 - Article

C2 - 28968984

AN - SCOPUS:85029813632

VL - 8

SP - 63232

EP - 63246

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 38

ER -